CLAIMS

- 1. Controlled dosage aerosol with at least one medicinal agent, a propellant, and lecithin as surface-active agent, characterized in that the said medicinal agent is present in the form of a suspension and that the said propellant is pressure-liquefied isobutane.
- 2. Controlled dosage aerosol according to claim 1, characterized in that the said medicinal agent is a glucocorticoid, said glucocorticoid preferably being selected from the group consisting of cortisol, prednisone, prednisolone, methylprednisolone, triamcinolone, prednylidene, fluocortolone, paramethasone, dexamethasone, betamethasone, flunisolide, fluticasone, beclomethasone, budesonide and/or their anti-asthmatically active derivatives and/or mixtures thereof.
- 3. Controlled dosage aerosol according to claim 1 or 2, characterized in that it corresponds to the formulation

Glucocorticoid 0.1% - 0.2% Lecithin 0.05% - 0.4% Isobutane 99.85% - 99.4% 4. Controlled dosage aerosol according to claim 1 or 2, characterized in that it corresponds to the formulation

Glucocorticoid 0.5% - 1.0% Lecithin 0.25% - 4.0% Isobutane 99.75% - 95.0%

- 5. Controlled dosage aerosol according to any one of the preceding claims, characterized in that the said lecithin is soybean lecithin.
- 6. Controlled dosage aerosol according to claim 1 or 2, characterized in that it corresponds to the formulation

Beclomethasone 0.1% - 2.5% Soybean lecithin 0.05% - 5.0% Isobutane 99.85% - 92.5%

7. Controlled dosage aerosol according to claim 1 or 2, characterized in that it corresponds to the formulation

Budesonide 0.1% - 2.5%

Soybean lecithin 0.05% - 5.0%

Isobutane 99.85% - 92.5%

- 8. Controlled dosage aerosol according to any one of the preceding claims, characterized in that the ratio of gluco-corticoid and soybean lecithin is 1:2, preferably 1:1, and with particular preference 1:0.5.
- 9. Controlled dosage aerosol according to any one of the preceding claims for treating allergic diseases in humans and animals, preferably for inhalation treatment of allergic diseases of the respiratory tract.
- 10. Controlled dosage aerosol according to any one of claims 1 to 8, for treating asthma or allergic rhinitis.
- 11. Process for the production of controlled dosage aerosols according to any one of the preceding claims, characterized in that isobutane as a propellant in liquid form, and lecithin as a surface-active agent in liquid form, and at least one medicinal agent as solid substance are mixed with one other, and that the liquid suspension is filled under pressure into the spray tin provided therefore.
- 12. Process according to claim 11, characterized in that after filling in the suspension the temperature is between -10 and +10°C.
- 13. Process according to claim 11 or 12, characterized in that after filling in the suspension, the valve of the spray tin is cleaned by filling the tin up with propellant.